MRUS MERUS B V

Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023

Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference 2023 on Wednesday, June 7, 2023 at 11:30 a.m. ET.

The webcast of the presentation will be contemporaneously available on the of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus

is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as . Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit and .

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.



Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
 

Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
EN
31/05/2023

Underlying

MRUSMERUS B V

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MERUS B V

Research Team ACF
  • Research Team ACF
AMGN AMGEN INC.
NOVN NOVARTIS AG ... (+11)

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

AMGN AMGEN INC.
NOVN NOVARTIS AG
MRK MERCK & CO. INC.
LLY ELI LILLY AND COMPANY
SAN SANOFI
MRUS MERUS B V
PFE PFIZER INC.
AZN ASTRAZENECA PLC
GLAXO GLAXOSMITHKLINE PHARMACEUTICALS
TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SUMM.L SUMMIT THERAPEUTICS
04/29/25 April 29, 2025 1 EN
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
TWEKA TKH GROUP N.V. CERT
MRUS MERUS B V
ARGX ARGEN-X SE
AUTL AUTOLUS THERAPEUTICS ADS
AKZA AKZO NOBEL N.V.
DEME DEME GROUP NV
04/28/25 April 28, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
MRUS MERUS B V

Merus Betting Big On Bispecifics: Merus As A Fantastic Opportunity “Ne...

Today we initiate coverage on the Dutch biotech company Merus. Merus offers a compelling investment opportunity, with its innovative antibody platforms, promising lead asset petosemtamab, robust pipeline, and strategic partnerships. The company's strong financial position and ambitious plans for 2025 and beyond position it to make a significant impact on the landscape of cancer treatment. We initiate coverage with a $ 59 TP and Buy rating.

04/28/25 April 28, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus gibt Annahme von Abstract zur Präsentation auf der ASCO®-Jahrest...

Merus gibt Annahme von Abstract zur Präsentation auf der ASCO®-Jahrestagung 2025 bekannt - Vorläufige klinische Daten zu Petosemtamab in Kombination mit Pembrolizumab bei 1L PD-L1+ r/m HNSCC für Posterpräsentation ausgewählt - Telefonkonferenz am Donnerstag, 22. Mai, um 17:30 Uhr Eastern Time zur Besprechung des vollständigen ASCO®-Datensatzes UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, April 24, 2025 (GLOBE NEWSWIRE) -- N.V. (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein Onkologieunternehmen, das innovative, multispezifische Volllängen-Antikörper und Anti...

April 24, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus annonce l’acceptation de son résumé pour présentation au congrès...

Merus annonce l’acceptation de son résumé pour présentation au congrès annuel 2025 de l’ASCO® - Le pétosemtamab en association avec le pembrolizumab en traitement de première intention d'un CETC r/m PD-L1+ : premières données cliniques provisoires sélectionnées pour une présentation sous forme d’affiche - Conférence téléphonique le jeudi 22 mai à 17 h 30 heure de l’Est (« HE ») pour discuter de l’ensemble de données complet présenté lors de l’ASCO® UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 24 avr. 2025 (GLOBE NEWSWIRE) -- N.V. (Nasdaq : MRUS) (« Merus », la « Société »...

April 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch